Evidence map›Paper›PMID 40426788›Full record

ReviewChildren (Basel, Switzerland)2025

Ocular Manifestations in Children with Vernal Keratoconjunctivitis.

Matteo Capobianco, Marco Zeppieri, Giuseppe Gagliano, Federico Visalli, Fabiana D'Esposito, Roberta Foti, Ludovica Cannizzaro, Daniele Tognetto, Caterina Gagliano

Abstract readReview
In one paragraph

Review in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matteo CapobiancoDepartment of Ophthalmology, University of Catania, 95123 Catania, Italy.ORCID 0009-0009-2969-8610
Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.ORCID 0000-0003-0999-5545
Giuseppe GaglianoDepartment of Ophthalmology, University of Catania, 95123 Catania, Italy.ORCID 0009-0006-0059-5253
Federico VisalliDepartment of Ophthalmology, University of Catania, 95123 Catania, Italy.ORCID 0009-0005-6710-2460
Fabiana D'EspositoImperial College Ophthalmic Research Group [ICORG] Unit, Imperial College, London NW1 5QH, UK.ORCID 0000-0002-7938-876X
Roberta FotiRheumatology Unit, Policlinico San Marco Hospital, 95121 Catania, Italy.ORCID 0000-0002-3074-4508
Ludovica CannizzaroDepartment of Ophthalmology, University of Catania, 95123 Catania, Italy.ORCID 0009-0001-7556-6952
Daniele TognettoDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy.
Caterina GaglianoDepartment of Medicine and Surgery, University of Enna "Kore", Piazza dell'Università, 94100 Enna, Italy.ORCID 0000-0001-8424-0068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVernal keratoconjunctivitis (VKC) is a chronic, recurrent, and frequently severe allergic ocular condition predominantly impacting children and adolescents in tropical and subtropical areas. It profoundly affects patients' quality of life owing to its chronic symptoms and possible vision-threatening effects. Notwithstanding progress in comprehending VKC, its ocular symptoms and therapeutic approaches necessitate ongoing assessment.

aimsThis review summarizes the main factors to consider when diagnosing, treating, and managing patients with VKC based on the current literature in this field.

methodsThis comprehensive review examined peer-reviewed literature from 2010 to 2024 obtained from PubMed. The selection criteria encompassed research addressing the clinical presentation, diagnostic difficulties, and therapy of visual symptoms in pediatric patients with VKC. The publications chosen were those focusing on those that elucidate the pathophysiology, consequences, and innovations in treatment methodologies.

resultsThe ocular manifestations of VKC are varied and characterized by prominent symptoms such as severe itching, photophobia, lacrimation, and a viscous mucoid discharge. Clinical manifestations range from conjunctival hyperemia and limbal thickening to severe consequences that jeopardize vision, including shield ulcers and keratoconus. Improvements in imaging techniques such as anterior segment optical coherence tomography (AS-OCT) and in vivo confocal microscopy have enhanced diagnostic accuracy. The pharmacological approach has transitioned to steroid-sparing techniques, prioritizing mast cell stabilizers, antihistamines, and immunomodulators such as cyclosporine. Novel therapies, including biologics that target interleukin pathways, demonstrate potential in refractory instances. Nonetheless, access to modern medicines is restricted in resource-limited environments.

conclusionsVKC poses considerable diagnostic and treatment difficulties due to its chronic nature and possible consequences. This review emphasizes the necessity for prompt diagnosis and customized management approaches to avert vision impairment. Despite considerable advancements in comprehending VKC's etiology and therapy, inequalities in access to sophisticated care highlight the necessity for global activities to guarantee equitable treatment alternatives.

Indexed as

evaporative dry eyelipid layer instabilitymeibomian gland dysfunctionvitamin A therapy

Identifiers

PMID40426788
PMCPMC12110089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.